Venofer (Iron Sucrose): Uses, Dosage & Side Effects
An intravenous iron replacement therapy for treating iron deficiency when oral iron supplements are inadequate or cannot be tolerated
Venofer (iron sucrose) is an intravenous iron preparation used to treat iron deficiency in patients who cannot take oral iron supplements or for whom oral iron therapy has been ineffective. It delivers elemental iron directly into the bloodstream as a complex of polynuclear iron(III) hydroxide in sucrose, allowing rapid replenishment of iron stores. Venofer is widely used in patients with chronic kidney disease (CKD) – particularly those on hemodialysis – as well as patients with iron deficiency anemia due to inflammatory bowel disease, heavy menstrual bleeding, or post-surgical states. Each milliliter contains 20 mg of elemental iron, and it is administered exclusively in clinical settings equipped to manage potential hypersensitivity reactions.
Quick Facts: Venofer
Key Takeaways
- Venofer is given intravenously when oral iron is not an option: It is prescribed when patients cannot tolerate oral iron supplements (due to gastrointestinal side effects), when oral iron has been ineffective, or when rapid iron replacement is clinically necessary.
- Must be administered in a medical setting: Because of the risk of hypersensitivity reactions including anaphylaxis, Venofer must only be given where trained staff and resuscitation equipment are immediately available. Patients are monitored for at least 30 minutes after each dose.
- Commonly used in chronic kidney disease: Venofer is a cornerstone of iron management in patients with CKD, especially those undergoing hemodialysis, where iron losses are frequent and oral iron absorption is often impaired.
- Generally well tolerated: The most common side effects are temporary metallic taste, nausea, low blood pressure, and injection site reactions. Serious allergic reactions are uncommon but patients with a history of drug allergies, asthma, or autoimmune conditions are at higher risk.
- Not recommended for children: Venofer is not recommended for use in pediatric patients. Use in the first trimester of pregnancy has not been studied, and the drug should be used during pregnancy only when clearly needed.
What Is Venofer and What Is It Used For?
Venofer (iron sucrose) is an intravenous iron preparation that delivers elemental iron directly into the bloodstream. It is used to treat iron deficiency in patients who cannot take or do not respond to oral iron supplements. It is particularly important for patients with chronic kidney disease on dialysis.
Iron is an essential mineral that the body needs to produce hemoglobin – the protein in red blood cells that carries oxygen from the lungs to every tissue and organ. Iron is also a critical component of myoglobin (which stores oxygen in muscles) and numerous enzymes involved in energy metabolism, DNA synthesis, and immune function. When the body’s iron stores become depleted, a condition known as iron deficiency develops, which can progress to iron deficiency anemia if hemoglobin levels fall below normal.
Iron deficiency is the most common nutritional deficiency worldwide, affecting an estimated 1.2 billion people according to the World Health Organization (WHO). While many patients can replenish their iron stores through dietary changes or oral iron supplements, a significant proportion cannot. Oral iron is often poorly tolerated due to gastrointestinal side effects such as nausea, constipation, abdominal cramping, and diarrhea. In some conditions – particularly chronic kidney disease, inflammatory bowel disease, and malabsorption syndromes – oral iron is poorly absorbed regardless of dose.
Venofer addresses these challenges by delivering iron directly into the bloodstream, completely bypassing the gastrointestinal tract. After intravenous administration, the iron sucrose complex is rapidly taken up by the reticuloendothelial system (primarily in the liver, spleen, and bone marrow), where the iron is released from its sucrose carrier and incorporated into hemoglobin for red blood cell production, stored as ferritin, or used in iron-dependent enzymatic processes.
When Is Venofer Prescribed?
Your doctor may prescribe Venofer in the following situations:
- Intolerance to oral iron: When oral iron supplements cause significant gastrointestinal side effects such as nausea, vomiting, constipation, or abdominal pain that prevent you from continuing treatment
- Failure of oral iron therapy: When you have taken oral iron supplements for an adequate duration without meaningful improvement in iron levels or hemoglobin
- Chronic kidney disease (CKD): Patients on hemodialysis lose iron regularly through the dialysis process and blood sampling, and often have impaired oral iron absorption due to uremia and concurrent medications
- Inflammatory bowel disease (IBD): Active inflammation in the gastrointestinal tract can severely impair oral iron absorption, making intravenous iron the preferred route
- Pre-operative and post-operative anemia: When rapid iron replenishment is needed before or after surgery to reduce the need for blood transfusions
- Pregnancy-related iron deficiency: In the second and third trimesters when oral iron is insufficient or not tolerated, and iron stores need urgent replenishment
After intravenous injection, the iron sucrose complex is rapidly cleared from the plasma with a terminal half-life of approximately 6 hours. The complex is taken up by macrophages in the reticuloendothelial system, where the iron is released and either incorporated into transferrin (for transport to the bone marrow) or stored as ferritin. Peak utilization of iron from Venofer for hemoglobin synthesis occurs approximately 6–9 days after administration. Unlike oral iron, which has a bioavailability of only 10–20%, intravenous iron achieves 100% bioavailability.
What Should You Know Before Receiving Venofer?
Before receiving Venofer, your doctor must ensure that your anemia is caused by iron deficiency and not by another condition. You must not receive Venofer if you are allergic to iron sucrose, have experienced severe allergic reactions to other injectable iron products, have iron overload, or have a disorder of iron utilization.
Contraindications – Do Not Receive Venofer If You:
- Are allergic (hypersensitive) to iron sucrose or any of the other ingredients in Venofer
- Have had serious allergic reactions to other injectable iron preparations in the past
- Have anemia that is not caused by iron deficiency (for example, megaloblastic anemia due to vitamin B12 or folate deficiency, hemolytic anemia, or anemia of chronic disease without iron deficiency)
- Have iron overload (excess iron in the body) or a disturbance of iron utilization such as hemochromatosis, hemosiderosis, or sideroblastic anemia
If you are uncertain whether any of these conditions apply to you, speak with your doctor before receiving Venofer. Your doctor will typically check your serum ferritin, transferrin saturation (TSAT), and hemoglobin levels before starting treatment to confirm iron deficiency and determine the appropriate total dose.
Warnings and Precautions
Tell your doctor or nurse before receiving Venofer if you:
- Have a history of drug allergies – patients with a history of allergic reactions to medications are at increased risk of hypersensitivity reactions to intravenous iron
- Have systemic lupus erythematosus (SLE) – autoimmune conditions may increase the risk of adverse reactions
- Have rheumatoid arthritis – similar autoimmune considerations apply
- Have severe asthma, eczema, or other allergies – atopic individuals may be more susceptible to hypersensitivity reactions
- Have an active infection – iron may promote bacterial growth and worsen infections; your doctor may delay treatment until the infection is controlled
- Have liver problems – the liver plays a central role in iron metabolism, and hepatic impairment can affect iron handling and increase the risk of iron overload
All intravenous iron preparations, including Venofer, carry a risk of hypersensitivity reactions that can be severe and potentially life-threatening (anaphylactic/anaphylactoid reactions). These reactions can occur even in patients who have previously tolerated Venofer without problems. This is why every dose must be administered in a clinical setting where trained staff and resuscitation equipment (including epinephrine, corticosteroids, and airway management tools) are immediately available. You will be observed for at least 30 minutes after each dose.
If Venofer leaks from the vein into the surrounding tissue during injection (extravasation), it can cause pain, inflammation, tissue necrosis, and permanent brown discoloration of the skin at the injection site. Your healthcare provider will ensure proper intravenous access before administration. If you experience pain, burning, or swelling at the injection site during administration, tell your nurse immediately.
Pregnancy and Breastfeeding
Venofer has not been studied in women during the first trimester of pregnancy. It is important to tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby. If you become pregnant during treatment, consult your doctor immediately. Your doctor will decide whether you should receive this medicine based on a careful assessment of the potential benefits versus the risks.
Iron deficiency anemia during pregnancy is associated with serious risks for both mother and baby, including preterm birth, low birth weight, and increased maternal morbidity. During the second and third trimesters, your doctor may determine that the benefits of intravenous iron replacement outweigh the potential risks, particularly if oral iron supplementation has failed or is not tolerated.
If you are breastfeeding, consult your doctor before receiving Venofer. Small amounts of iron from iron sucrose may pass into breast milk. Your doctor will assess whether treatment is necessary and advise you accordingly.
Driving and Operating Machinery
You may feel dizzy, confused, or light-headed after receiving Venofer. If you experience any of these effects, do not drive or operate machinery until the symptoms have resolved. These effects are usually temporary and subside within a few hours after the infusion.
Sodium Content
Venofer contains up to 7 mg of sodium per milliliter. This corresponds to approximately 0.4% of the WHO recommended maximum daily sodium intake for adults (2 g/day). This should be taken into consideration if you are on a controlled sodium diet.
How Does Venofer Interact with Other Drugs?
Venofer has relatively few drug interactions compared to many other medications. The most important interaction is with oral iron supplements, which may become less effective if taken concurrently with Venofer. Do not take oral iron supplements for at least 5 days after your last Venofer dose.
Because Venofer is administered intravenously and its iron is rapidly taken up by the reticuloendothelial system, it has a relatively limited interaction profile. However, there are some important considerations that both patients and healthcare providers should be aware of:
Interactions with Oral Iron
The most clinically significant interaction involves oral iron supplements. When Venofer and oral iron are given concurrently or in close temporal proximity, the absorption of oral iron from the gastrointestinal tract is significantly reduced. This occurs because the rapid increase in serum iron levels from the intravenous dose upregulates hepcidin – a key iron-regulatory hormone produced by the liver – which in turn blocks the absorption of dietary and supplemental iron from the intestine.
For this reason, healthcare guidelines recommend that oral iron supplements should not be started until at least 5 days after the last Venofer administration. If you are already taking oral iron, your doctor may instruct you to stop it before beginning Venofer treatment.
| Drug / Class | Interaction | Recommendation |
|---|---|---|
| Oral iron supplements | Reduced absorption of oral iron due to hepcidin upregulation from IV iron | Do not take oral iron for at least 5 days after Venofer; discuss timing with your doctor |
| Dimercaprol (chelating agent) | Dimercaprol forms toxic complexes with iron, potentially causing kidney damage | Avoid concurrent use; do not administer within 24 hours of dimercaprol |
| Chloramphenicol | May delay the response to iron therapy by inhibiting erythropoiesis | Monitor hemoglobin response; consider alternative antibiotics if possible |
| ACE inhibitors | Increased risk of hypersensitivity reactions in some case reports | Monitor closely during and after infusion; be aware of increased reaction risk |
Compatibility and Incompatibility
Venofer must not be mixed with any other medications except sterile 0.9% sodium chloride (normal saline) solution. Mixing Venofer with other solutions or drugs risks precipitation and chemical interaction, which could cause adverse reactions or render the medication ineffective. Compatibility has been documented with glass, polyethylene, and PVC containers only; compatibility with other container materials has not been established.
Always inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. While Venofer has a limited drug interaction profile, your doctor needs a complete medication list to ensure safe and effective treatment.
What Is the Correct Dosage of Venofer?
Venofer dosage is individualized based on your body weight, hemoglobin level, and the severity of your iron deficiency. Your doctor calculates the total iron dose needed and divides it into multiple sessions. Typical individual doses range from 100 to 200 mg of iron per session, administered 1 to 3 times per week.
The total amount of Venofer you need is determined by your doctor using a formula that takes into account your current hemoglobin level, target hemoglobin level, and body weight. Your doctor will also take a blood test (serum ferritin and transferrin saturation) to confirm the degree of iron deficiency and help calculate the total iron deficit.
Administration Methods
Your doctor or nurse will administer Venofer using one of the following methods:
- Slow intravenous injection: Undiluted Venofer is injected directly into a vein at a rate of no more than 1 ml (20 mg iron) per minute. The maximum dose per injection is 10 ml (200 mg iron).
- Intravenous infusion (drip): Venofer is diluted in sterile 0.9% sodium chloride solution and infused over a period of time that depends on the dose.
- During hemodialysis: Venofer can be administered directly into the venous line of the dialysis machine during a hemodialysis session, under the same conditions as an intravenous injection.
Regardless of the method, Venofer is typically administered 1 to 3 times per week until the calculated total iron dose has been delivered.
Infusion Dilution and Timing Guidelines
| Iron Dose | Venofer Volume | Max Dilution (0.9% NaCl) | Minimum Infusion Time |
|---|---|---|---|
| 50 mg | 2.5 ml | 50 ml | 8 minutes |
| 100 mg | 5 ml | 100 ml | 15 minutes |
| 200 mg | 10 ml | 200 ml | 30 minutes |
Venofer must not be diluted to concentrations lower than those shown in the table above, as this may compromise the stability of the iron sucrose complex. The diluted solution should be used immediately after preparation.
Adults
Standard Adult Dosing
The typical dose for adults is 100–200 mg of iron (5–10 ml of Venofer) per administration, given 1 to 3 times per week. The total cumulative dose is determined by the calculated iron deficit. Most adult patients require a total of 1,000 mg of iron (ten 100 mg doses or five 200 mg doses) to replenish iron stores, though this can vary widely depending on the severity of depletion.
For hemodialysis patients, a common regimen is 100 mg of iron (5 ml) administered during each of 10 consecutive dialysis sessions, totaling 1,000 mg. Maintenance doses may then be given periodically based on ongoing iron loss.
Children
Pediatric Use
Venofer is not recommended for use in children. The safety and efficacy of Venofer in the pediatric population have not been adequately established. If intravenous iron therapy is required in a pediatric patient, your doctor will consider alternative formulations with established pediatric data.
Elderly
Geriatric Dosing
No specific dose adjustment is required for elderly patients. However, elderly patients may be more susceptible to hypotension and other cardiovascular effects during infusion, so careful monitoring is recommended. Renal and hepatic function should be assessed before treatment, as these may be reduced in older adults.
Overdose
Administering Venofer at doses exceeding the calculated iron deficit can lead to iron overload (hemosiderosis), which manifests as excess iron deposition in tissues – particularly the liver, heart, and endocrine organs. Signs of acute iron overload may include nausea, vomiting, abdominal pain, and hemodynamic instability.
Because Venofer is always administered by healthcare professionals in a controlled setting, accidental overdose is rare. If iron overload is suspected, your doctor will monitor serum ferritin and transferrin saturation levels and may initiate chelation therapy (with deferoxamine) in severe cases. Venofer cannot be removed by hemodialysis.
What Are the Side Effects of Venofer?
Like all medicines, Venofer can cause side effects, although not everyone experiences them. The most common side effects include temporary metallic taste, changes in blood pressure, nausea, and injection site reactions. Allergic reactions are uncommon but can be serious. Tell your doctor or nurse immediately if you experience any signs of an allergic reaction during or after the infusion.
Side effects from Venofer are generally mild to moderate and transient. The infusion is well tolerated by most patients, particularly compared to oral iron supplements which frequently cause gastrointestinal disturbances. However, all intravenous iron preparations carry a small risk of hypersensitivity reactions, which is why patients are monitored during and after each administration.
Tell your doctor or nurse immediately if you notice any of the following during or after receiving Venofer: low blood pressure (feeling dizzy, light-headed, or faint), swelling of the face, lips, tongue, or throat, difficulty breathing or wheezing, chest pain (which may be a sign of Kounis syndrome). In rare cases, these reactions can be severe or life-threatening (anaphylactic/anaphylactoid reactions). Your healthcare team is trained to recognize and treat these reactions promptly.
Common
May affect up to 1 in 10 people
- Temporary taste disturbances (especially metallic taste)
- Low blood pressure (hypotension) or high blood pressure (hypertension)
- Nausea
- Injection/infusion site reactions: pain, irritation, itching, bruising, or skin discoloration from extravasation
Uncommon
May affect up to 1 in 100 people
- Headache or dizziness
- Abdominal pain or diarrhea
- Vomiting
- Wheezing or difficulty breathing
- Itching (pruritus) or skin rash
- Muscle spasms, cramps, or muscle pain
- Tingling or numbness (paresthesia)
- Decreased sense of touch (hypoesthesia)
- Vein inflammation (phlebitis)
- Flushing or burning sensation
- Constipation
- Joint pain (arthralgia)
- Pain in arms or legs
- Back pain
- Chills
- Weakness or fatigue (asthenia)
- Swollen hands and feet (peripheral edema)
- Pain
- Elevated liver enzymes (ALT, AST, gamma-GT)
- Elevated serum ferritin levels
Rare
May affect up to 1 in 1,000 people
- Fainting (syncope)
- Drowsiness or somnolence
- Rapid heartbeat (palpitations)
- Changes in urine color
- Chest pain
- Increased sweating
- Fever
- Elevated lactate dehydrogenase (LDH) levels
Frequency Not Known
Cannot be estimated from available data
- Decreased alertness or confusion
- Loss of consciousness
- Anxiety, tremor, or shaking
- Swelling of face, mouth, tongue, or throat (angioedema) potentially causing breathing difficulties
- Slow or rapid pulse
- Circulatory collapse
- Vein inflammation with blood clot formation (thrombophlebitis)
- Acute bronchospasm (airway narrowing)
- Hives (urticaria), other skin rashes, or skin redness
- Cold sweats
- General malaise or pallor
- Sudden life-threatening allergic reactions (anaphylaxis)
- Flu-like illness (occurring hours to days after injection, characterized by fever, muscle and joint aches)
Reporting Side Effects
It is important to report any suspected side effects after a medicine has been authorized. This helps to continuously monitor the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority. In the United States, adverse events can be reported to the FDA MedWatch program. In the European Union, reports can be submitted to the national competent authority of the relevant member state.
How Should Venofer Be Stored?
Venofer should be stored at or below 25°C (77°F), must not be frozen, and should be kept in its original packaging. Once opened, ampoules or vials must be used immediately. Venofer is normally stored by your healthcare facility – you do not need to store it at home.
Venofer is a sterile product that requires specific storage conditions to maintain its stability and efficacy:
- Temperature: Store at no more than 25°C (77°F). Do not freeze. If the product has been accidentally frozen, it must be discarded.
- Light protection: Keep the ampoules or vials in the original carton to protect from light.
- After opening: Once an ampoule or vial is opened, the contents must be used immediately. Do not store opened containers for later use.
- After dilution: When diluted with 0.9% sodium chloride solution for infusion, the diluted solution should be used immediately after preparation due to microbiological considerations.
- Inspection before use: Before administration, check for visible precipitate or particles and ensure the container is not damaged. Only use solutions that are homogeneous and free of precipitate. The solution should appear dark brown and non-transparent.
- Expiry date: Do not use Venofer after the expiry date printed on the label (EXP).
Keep this medicine out of the sight and reach of children. Unused medicine and waste materials should be disposed of in accordance with local regulations for pharmaceutical waste.
What Does Venofer Contain?
The active ingredient in Venofer is iron in the form of iron sucrose. Each milliliter contains 20 mg of elemental iron. The other ingredients are water for injection and sodium hydroxide (for pH adjustment). Venofer is a dark brown, opaque aqueous solution.
Active Ingredient
Each milliliter of Venofer contains 20 mg of iron as iron(III) hydroxide sucrose complex (iron sucrose). The iron is complexed with sucrose in a polynuclear structure that provides stability and allows controlled release of iron after intravenous administration.
Other Ingredients (Excipients)
- Water for injection
- Sodium hydroxide (for pH adjustment)
What Venofer Looks Like
Venofer is a dark brown, non-transparent (opaque) aqueous solution. It is available in the following presentations:
- Glass ampoules: 5 ml ampoules (containing 100 mg iron), supplied in packs of 5
- Glass vials: 5 ml vials (containing 100 mg iron), supplied in packs of 5
Not all pack sizes may be available in all countries. The injection or infusion solution also appears dark brown when prepared for administration.
Frequently Asked Questions About Venofer
Venofer (iron sucrose) is an intravenous iron replacement therapy that delivers elemental iron directly into the bloodstream. It is given intravenously because some patients cannot absorb sufficient iron through the gastrointestinal tract (due to conditions like chronic kidney disease, inflammatory bowel disease, or malabsorption) or cannot tolerate oral iron supplements due to side effects such as nausea, constipation, and abdominal pain. The intravenous route ensures 100% bioavailability of the iron, allowing rapid and reliable replenishment of iron stores.
The duration depends on the dose and administration method. When given as a slow intravenous injection, a 100 mg dose (5 ml) takes at least 5 minutes. When given as an intravenous infusion (drip), the minimum times are: 8 minutes for 50 mg, 15 minutes for 100 mg, and 30 minutes for 200 mg. After the infusion, you will be observed for at least 30 minutes for signs of allergic reactions. The total visit time typically ranges from 45 minutes to 1.5 hours including the observation period.
The number of treatments depends on your individual iron deficit, which your doctor calculates based on your body weight, hemoglobin level, and iron stores. Most adult patients require a total of approximately 1,000 mg of iron, which is typically divided into 5 to 10 sessions (depending on whether 100 mg or 200 mg is given per session). Sessions are usually scheduled 1 to 3 times per week. Hemodialysis patients often receive 100 mg per dialysis session over 10 sessions. Your doctor will monitor your blood tests to determine when the total dose has been administered and whether additional maintenance doses are needed.
Yes, Venofer can occasionally cause changes in urine color, making it appear darker than usual. This is a harmless effect related to the iron being processed by the body and does not indicate a problem. Similarly, Venofer is a dark brown solution, so the injection or infusion itself appears brown. If you experience any other unusual symptoms along with urine color changes (such as pain, fever, or blood in the urine), contact your doctor as these may indicate a different underlying issue.
Several intravenous iron formulations are available, including iron sucrose (Venofer), ferric carboxymaltose (Ferinject/Injectafer), iron dextran (CosmoFer/INFeD), and ferric derisomaltose (Monofer/MonoFerric). Each has a different carbohydrate shell surrounding the iron core, which affects the maximum single dose, infusion time, and side effect profile. Venofer is one of the most extensively studied IV iron products with over 25 years of clinical experience. Its maximum single dose is 200 mg of iron, which is lower than some newer formulations (ferric carboxymaltose allows up to 1,000 mg per infusion). However, Venofer has an excellent safety record and remains one of the most widely used IV iron preparations worldwide, particularly in the nephrology setting.
If you experience any symptoms during the infusion – such as dizziness, difficulty breathing, chest tightness, skin rash, itching, swelling, nausea, or a rapid heartbeat – tell your nurse or doctor immediately. The infusion can be slowed or stopped if needed. Healthcare professionals administering Venofer are trained to recognize and manage hypersensitivity reactions and have emergency equipment and medications readily available. Most adverse reactions during infusion are mild and resolve quickly when the infusion rate is reduced or the infusion is stopped.
References & Sources
This article is based on the following evidence-based sources and international medical guidelines:
- 1 European Medicines Agency (EMA). “Venofer – Summary of Product Characteristics (SmPC).” European public assessment report. Available at: www.ema.europa.eu
- 2 U.S. Food and Drug Administration (FDA). “Venofer (iron sucrose injection, USP) – Prescribing Information.” Approved labeling. Available at: www.accessdata.fda.gov
- 3 KDIGO (Kidney Disease: Improving Global Outcomes). “Clinical Practice Guideline for Anemia in Chronic Kidney Disease.” Kidney International Supplements, 2012; 2(4): 279–335.
- 4 Auerbach M, Adamson JW. “How we diagnose and treat iron deficiency anemia.” American Journal of Hematology, 2016; 91(1): 31–38. DOI: 10.1002/ajh.24201
- 5 World Health Organization (WHO). “Iron Deficiency Anaemia: Assessment, Prevention and Control – A Guide for Programme Managers.” WHO/NHD/01.3, Geneva, 2001.
- 6 NICE (National Institute for Health and Care Excellence). “Chronic kidney disease: managing anaemia.” NICE guideline [NG8], updated 2021. Available at: www.nice.org.uk/guidance/ng8
- 7 Macdougall IC, Bircher AJ, Eckardt K-U, et al. “Iron management in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference.” Kidney International, 2016; 89(1): 28–39.
- 8 Auerbach M, Macdougall IC. “Safety of intravenous iron formulations: facts and folklore.” Blood Advances, 2018; 2(2): 101–106. DOI: 10.1182/bloodadvances.2017011197
- 9 British National Formulary (BNF). “Iron sucrose.” Treatment summaries: anaemia, iron deficiency. Available at: bnf.nice.org.uk
- 10 Rampton D, Folkersen J, Fishbane S, et al. “Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.” Haematologica, 2014; 99(11): 1671–1676. DOI: 10.3324/haematol.2014.111492
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed physicians, pharmacists, and medical writers with expertise in clinical pharmacology, hematology, and nephrology.
Content developed by medical professionals with expertise in pharmacology and iron replacement therapy. All information is translated from regulatory-approved product information and enriched with current clinical guidelines and peer-reviewed evidence.
Independently reviewed by the iMedic Medical Review Board, comprising board-certified specialists who verify clinical accuracy, completeness, and adherence to international guidelines (WHO, EMA, FDA, KDIGO, NICE, BNF).
Evidence Level: 1A – Based on systematic reviews, meta-analyses of randomized controlled trials, and international clinical practice guidelines. All medical claims are verified against the current Summary of Product Characteristics (SmPC) and FDA-approved prescribing information.
Conflict of Interest: None. iMedic receives no funding from pharmaceutical companies and maintains complete editorial independence.
Last Medical Review: